Cancer drug combo trial halted early – what we know
NCT ID NCT04276376
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tested a combination of two drugs, rucaparib and atezolizumab, in 130 adults with advanced solid tumors that have specific DNA repair problems or are sensitive to platinum chemotherapy. The goal was to see if the combination could shrink tumors. However, the study was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rucaparib and atezolizumab
- What this could lead to
- If successful, this combination could offer a new treatment option for certain hard-to-treat solid tumors.
- What could go wrong
- The trial was terminated early, so results are limited. It is a small, early-phase study, and the combination may not work for all tumor types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gustave Roussy
Villejuif, Val De Marne, 94800, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new pill outsmart resistant prostate cancer?
- Can a Tumor's DNA guide better cancer care for kids?